Q2 Earnings Skimmed thru Tilrays ER yesterday; didn't give a warm & fuzzy feeling for Medipharm's Q2 and worries me that we won't see major top line growth until Q3, but we'll find out in the next couple weeks.
I also love some of the reporting metrics "adjusted net income" & "adjusted free cash flow" - these "adjusted" metrics are starting to get out of hand lol.